Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Randall P SharpRiaz Sirajuddin

Abstract

Elevated levels of triglycerides are associated with pancreatitis and an increased risk of coronary heart disease. Numerous pharmacologic therapies are available to treat hypertriglyceridemia, including prescription omega-3 fatty acids, which reduce triglyceride levels by 20-50%. Available data indicate the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may be beneficial for secondary prevention of coronary heart disease. Products containing DHA may increase low-density lipoprotein cholesterol (LDL-C) and, subsequently, coronary heart disease risk. We reviewed prescription omega-3 fatty acid products, of which two-omega-3 acid ethyl esters (OM3EE) and omega-3 carboxylic acid (OM3CA)-contain both DHA and EPA, whereas the other-icosapent ethyl (IPE)-contains EPA only. We identified three retrospective chart reviews and three case reports comparing IPE with OM3EE, whereas two studies compared IPE with placebo. We also reviewed the major studies of OM3EE versus placebo used to gain US FDA approval. LDL-C levels decreased or did not increase significantly in all available studies and case reports in patients receiving the IPE product, with the best data supporting a dose of 4 g per day. The majority o...Continue Reading

References

Dec 29, 1998·Journal of Cardiovascular Risk·W S HarrisK Osmundsen
Apr 3, 2007·Lancet·Mitsuhiro YokoyamaUNKNOWN Japan EPA lipid intervention study (JELIS) Investigators
Sep 11, 2007·Clinical Therapeutics·Michael H DavidsonUNKNOWN COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators
Apr 20, 2011·Circulation·Michael MillerUNKNOWN Council on the Kidney in Cardiovascular Disease
Aug 21, 2012·Journal of Lipid Research·Donald B JumpSasmita Tripathy
Feb 12, 2014·Clinical Medicine Insights. Cardiology·Daniel E Hilleman, Mark A Malesker
May 24, 2016·Canadian Pharmacists Journal : CPJ = Revue Des Pharmaciens Du Canada : RPC·Courtney P WalzSheri L Koshman
Oct 18, 2016·Current Treatment Options in Cardiovascular Medicine·Kate J BowenPenny M Kris-Etherton
Feb 1, 2017·Lipids in Health and Disease·Eliot A Brinton, R Preston Mason
Mar 16, 2017·Circulation·David S SiscovickUNKNOWN American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiolo

❮ Previous
Next ❯

Citations

Jan 13, 2018·International Journal of Molecular Sciences·Alex Buoite StellaMichela Zanetti

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.